Leap Therapeutics, Inc.
LPTX
$0.3634
-$0.0056-1.52%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | 16.74% | 20.31% | 27.10% | 38.00% | -49.12% |
| Total Depreciation and Amortization | -66.67% | -40.00% | 106.32% | 33.33% | -6.25% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -82.37% | -86.78% | -85.70% | -85.56% | 467.88% |
| Change in Net Operating Assets | -48.63% | 609.96% | 416.79% | 394.25% | 485.71% |
| Cash from Operations | -37.82% | -18.93% | -3.95% | 7.28% | 10.79% |
| Capital Expenditure | -- | 100.00% | 100.00% | 66.70% | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -100.00% | -100.00% | -100.00% | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -100.00% | -100.00% | -100.71% | -- |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | -- | 100.00% | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -10,065.52% | -10,065.52% | -9,837.93% | 100.00% | 86.19% |
| Cash from Financing | 124,046.67% | 123,700.00% | 128,186.21% | 196.55% | 85.71% |
| Foreign Exchange rate Adjustments | -548.84% | 242.74% | 89.84% | 6.56% | 73.46% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -554.87% | -835.93% | -2,531.58% | -3,886.21% | 110.41% |